Improved survival from ovarian cancer in patients treated in phase III trial active cancer centres in the UK.
Name:
PIIS0936655516301674.pdf
Size:
267.5Kb
Format:
PDF
Description:
Open access full text article
Authors
Khoja, LeilaNolan, K
Mekki, R
Milani, A
Mescallado, Nerissa
Ashcroft, Linda
Hasan, Jurjees
Edmondson, R
Winter-Roach, Brett
Kitchener, H C
Mould, T
Hutson, R
Hall, G
Clamp, Andrew R
Perren, T
Ledermann, J
Jayson, Gordon C
Affiliation
The Christie NHS Foundation Trust and Institute of Cancer Sciences, University of ManchesterIssue Date
2016-07-09
Metadata
Show full item recordAbstract
Ovarian cancer is the principal cause of gynaecological cancer death in developed countries, yet overall survival in the UK has been reported as being inferior to that in some Western countries. As there is a range of survival across the UK we hypothesised that in major regional centres, outcomes are equivalent to the best internationally.Citation
Improved survival from ovarian cancer in patients treated in phase III trial active cancer centres in the UK. 2016: Clin Oncol (R Coll Radiol)Journal
Clinical OncologyDOI
10.1016/j.clon.2016.06.011PubMed ID
27401967Type
ArticleLanguage
enISSN
1433-2981ae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2016.06.011
Scopus Count
Collections
Related articles
- A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
- Authors: Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G
- Issue date: 2001
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
- Authors: Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ, ICON7 trial investigators
- Issue date: 2015 Aug
- Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
- Authors: Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
- Issue date: 2017 Jun
- Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
- Authors: Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P
- Issue date: 2022 Feb 1
- Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
- Authors: Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S, EORTC, MRC CHORUS study investigators
- Issue date: 2018 Dec